サマリー

ラテンアメリカのG-CSF/PEG-G-CSF市場は、2023年から2030年の予測期間に5.9%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションを行います：
ラテンアメリカのG-CSF/PEG-G-CSF市場、適応症別（好中球減少症、腫瘍、慢性・自己免疫疾患、血液疾患、成長調和不全、その他）、投与量（単剤、配合剤）、投与経路（静脈内、皮下）、包装（単剤バイアル、プレフィルドシリンジ)、エンドユーザー（病院・クリニック、研究・学術機関、外来手術センター、その他）、流通チャネル（病院薬局、オンライン薬局、小売薬局、その他）、国（メキシコ、コロンビア、ブラジル、アルゼンチン、チリ、ペルー、エクアドル、LATAMの残り）の産業動向と2030年までの予測

中南米のG-CSF/PEG-G-CSF市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 血液のがんやがん疾患の増加
- 発熱性好中球減少症の増加例
市場のプレーヤー：

中南米のG-CSF/PEG-G-CSF市場で活動している主要な市場関係者は以下の通りです：
- ルパン
- インタス・ファーマシューティカルズ・リミテッド（Intas Pharmaceuticals Ltd.
- バイオシダス
- カシブ・バイオサイエンス・エルエルシー
- STADA Arzneimittel AG
- USVプライベート・リミテッド
- ヴィアトリス・インク
- フレゼニウス・カビAG
- アムジェン社
- ファイザー株式会社
- サンド・インターナショナル社
- アポテックス・インク
- カディラ・ファーマシューティカルズ
- ドクターレディーズラボラトリーズLtd.
- アムニール・ファーマシューティカルズLLC
- コーヘラス・バイオサイエンス
- アコードヘルスケア
- ナップ・ファーマシューティカルズ・リミテッド
- インタス・ファーマシューティカルズ・リミテッド
- ムンディファーマ・インターナショナル
- テバ・ファーマシューティカル・インダストリーズ社
- スペクトラム・ファーマシューティカルズ・インク
- 協和キリン(株)
- 江蘇恒瑞医薬有限公司

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 50
1.1 OBJECTIVES OF THE STUDY 50
1.2 MARKET DEFINITION 50
1.3 OVERVIEW OF LATIN AMERICA G-CSF / PEG-G-CSF MARKET 50
1.4 LIMITATIONS 52
1.5 MARKETS COVERED 52
2 MARKET SEGMENTATION 55
2.1 MARKETS COVERED 55
2.2 GEOGRAPHICAL SCOPE 56
2.3 YEARS CONSIDERED FOR THE STUDY 57
2.4 CURRENCY AND PRICING 57
2.5 DBMR TRIPOD DATA VALIDATION MODEL 58
2.6 MULTIVARIATE MODELLING 61
2.7 TYPE LIFELINE CURVE 61
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 62
2.9 DBMR MARKET POSITION GRID 63
2.10 MARKET END USER COVERAGE GRID 64
2.11 VENDOR SHARE ANALYSIS 65
2.12 SECONDARY SOURCES 66
2.13 ASSUMPTIONS 66
3 EXECUTIVE SUMMARY 67
4 PREMIUM INSIGHTS 70
4.1 PESTEL ANALYSIS 71
4.2 PORTER’S FIVE FORCES 72
4.3 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: MERGERS AND ACQUISITION 73
4.4 LATIN AMERICA G-CSF / PEG-G-CSF MARKET 74
4.5 STRATEGIES TO THE ENTER THE MARKET 74
4.5.1 JOINT VENTURE (PARTNERSHIPS): 74
4.5.2 ACQUISITION: 74
4.5.3 LINE EXPANSION VIA COLLABORATION: 74
4.5.4 PRODUCT APPROVAL: 75
4.5.5 PRODUCT LAUNCH: 75
4.5.6 GEOGRAPHIC EXPANSION: 75
4.5.7 COST LEADERSHIP: 76
4.5.8 PRODUCT DEVELOPMENT: 76
4.6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET, INDUSTRY INSIGHTS 77
4.6.1 PATENT ANALYSIS 77
4.6.2 DRUG TREATMENT RATE BY MATURED MARKETS 78
4.6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 78
4.6.4 THERAPEUTIC ASSESSMENT 78
4.6.5 KEY PRICING STRATEGIES 79
4.6.6 KEY PATIENT ENROLLMENT STRATEGIES 79
4.6.7 CONCLUSION 79
4.7 PIPELINE ANALYSIS FOR LATIN AMERICA G-CSF / PEG-G-CSF MARKET 80
5 EPIDEMIOLOGY 81
6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: REGULATIONS 84
7 MARKET OVERVIEW 87
7.1 DRIVERS 89
7.1.1 GROWING INCIDENCES OF BLOOD CANCERS AND CANCER DISEASES 89
7.1.2 RISING INCIDENCES OF AUTOIMMUNE DISORDERS 90
7.1.3 INCREASING CASES OF FEBRILE NEUTROPENIA 91
7.1.4 INCREASING AWARENESS ABOUT FILGRASTIM AND PEGFILGRASTIM 92
7.2 RESTRAIN 93
7.2.1 STRINGENT GOVERNMENTAL REGULATIONS 93
7.2.2 AVAILABILITY OF ALTERNATIVES FOR THE CHEMOTHERAPY 94
7.3 OPPORTUNITIES 95
7.3.1 THE USE OF BIOSIMILARS HELPS REDUCE HEALTHCARE COSTS FOR PATIENTS 95
7.3.2 COST-EFFECTIVENESS AND PATENT EXPIRY OF BIOLOGICAL PRODUCTS 95
7.4 CHALLENGES 96
7.4.1 THE HIGH COST ASSOCIATED WITH BRANDED BIOLOGICS AND IMPROVED CHEMOTHERAPY 96
7.4.2 THE MULTIPLE SIDE EFFECTS OF G-CSF 96
8 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION 97
8.1 OVERVIEW 98
8.2 NEUTROPENIA 102
8.2.1 CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA (MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT) 103
8.2.2 SEVERE CHRONIC NEUTROPENIA 103
8.2.3 RADIOTHERAPY INDUCED NEUTROPENIA 103
8.2.4 NEUTROPENIA IN HIV PATIENTS 103
8.2.5 CLOZAPINE INDUCED NEUTROPENIA 103
8.2.6 NEUTROPENIA IN HEPATITIS C PATIENTS 103
8.2.7 CONGENITAL NEUTROPENIA 103
8.3 ONCOLOGY 104
8.3.1 ACUTE MYELOID LEUKEMIA RECEIVING CONSOLIDATION CHEMOTHERAPY 104
8.3.2 OTHERS 105
8.4 CHRONIC AND AUTO IMMUNE DISEASES 105
8.5 BLOOD DISORDERS 105
8.6 GROWTH HORMONE DEFICIENCY 106
8.7 OTHERS 107
9 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE 108
9.1 OVERVIEW 109
9.2 MONO 112
9.3 COMBINATION 113
10 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION 114
10.1 OVERVIEW 115
10.2 SUBCUTANEOUS 118
10.3 INTRAVENOUS 119
11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING 120
11.1 OVERVIEW 121
11.2 PRE FILLED SYRINGES 124
11.3 SINGLE USE VIALS 125
12 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER 126
12.1 OVERVIEW 127
12.2 HOSPITALS AND CLINICS 130
12.3 RESEARCH & ACADEMIC INSTITUTES 130
12.4 AMBULATORY SURGICAL CENTERS 131
12.5 OTHERS 132
13 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL 133
13.1 OVERVIEW 134
13.2 HOSPITALS PHARMACY 137
13.3 RETAIL PHARMACY 137
13.4 ONLINE PHARMACY 138
13.5 OTHERS 139
14 LATIN AMERICA G-CSF/PEG-G-CSF MARKET, BY REGION 140
14.1 LATIN AMERICA 141
14.1.1 MEXICO 147
14.1.2 COLUMBIA 155
14.1.3 BRAZIL 162
14.1.4 ARGENTINA 170
14.1.5 CHILE 180
14.1.6 PERU 187
14.1.7 ECUADOR 194
15 LATIN AMERICA G-CSF / PEG-G-CSF MARKET, COMPANY LANDSCAPE 202
15.1 COMPANY SHARE ANALYSIS: LATIN AMERICA 202
16 SWOT ANALYSIS 203
17 COMPANY PROFILE 204
17.1 PFIZER INC. 204
17.1.1 COMPANY SNAPSHOT 204
17.1.2 REVENUE ANALYSIS 205
17.1.3 COMPANY SHARE ANALYSIS 205
17.1.4 PRODUCT PORTFOLIO 206
17.1.5 RECENT DEVELOPMENTS 206
17.2 VIATRIS INC. 207
17.2.1 COMPANY SNAPSHOT 207
17.2.2 REVENUE ANALYSIS 207
17.2.3 COMPANY SHARE ANALYSIS 208
17.2.4 PRODUCT PORTFOLIO 208
17.2.5 RECENT DEVELOPMENT 208
17.3 AMGEN INC. 209
17.3.1 COMPANY SNAPSHOT 209
17.3.2 REVENUE ANALYSIS 209
17.3.3 COMPANY SHARE ANALYSIS 210
17.3.4 PRODUCT PORTFOLIO 210
17.3.5 RECENT DEVELOPMENTS 210
17.4 STADA ARZENEIMITTEL AG 212
17.4.1 COMPANY SNAPSHOT 212
17.4.2 COMPANY SHARE ANALYSIS 212
17.4.3 PRODUCT PORTFOLIO 213
17.4.4 RECENT DEVELOPMENT 213
17.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 214
17.5.1 COMPANY SNAPSHOT 214
17.5.2 REVENUE ANALYSIS 214
17.5.3 COMPANY SHARE ANALYSIS 215
17.5.4 PRODUCT PORTFOLIO 215
17.5.5 RECENT DEVELOPMENTS 215
17.6 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. 216
17.6.1 COMPANY SNAPSHOT 216
17.6.2 PRODUCT PORTFOLIO 216
17.6.3 RECENT DEVELOPMENTS 216
17.7 ACCORD HEALTHCARE 217
17.7.1 COMPANY SNAPSHOT 217
17.7.2 PRODUCT PORTFOLIO 217
17.7.3 RECENT DEVELOPMENTS 217
17.8 AMNEAL PHARMACEUTICALS LLC. 218
17.8.1 COMPANY SNAPSHOT 218
17.8.2 REVENUE ANALYSIS 218
17.8.3 PRODUCT PORTFOLIO 219
17.8.4 RECENT DEVELOPMENTS 219
17.9 APOTEX INC. 220
17.9.1 COMPANY SNAPSHOT 220
17.9.2 PRODUCT PORTFOLIO 220
17.9.3 RECENT DEVELOPMENT 220
17.10 BIOCON 221
17.10.1 COMPANY SNAPSHOT 221
17.10.2 REVENUE ANALYSIS 221
17.10.3 PRODUCT PORTFOLIO 222
17.10.4 RECENT DEVELOPMENT 222
17.11 BIO SIDUS 223
17.11.1 COMPANY SNAPSHOT 223
17.11.2 PRODUCT PORTFOLIO 223
17.11.3 RECENT DEVELOPMENTS 223
17.12 CADILA PHARMACEUTICALS 224
17.12.1 COMPANY SNAPSHOT 224
17.12.2 PRODUCT PORTFOLIO 224
17.12.3 RECENT DEVELOPMENTS 224
17.13 COHERUS BIOSCIENCES 225
17.13.1 COMPANY SNAPSHOT 225
17.13.2 REVENUE ANALYSIS 225
17.13.3 PRODUCT PORTFOLIO 226
17.13.4 RECENT DEVELOPMENT 226
17.14 DR. REDDY’S LABORATORIES LTD 227
17.14.1 COMPANY SNAPSHOT 227
17.14.2 REVENUE ANALYSIS 227
17.14.3 PRODUCT PORTFOLIO 228
17.14.4 RECENT DEVELOPMENTS 228
17.15 FRESENIUS KABI AG 229
17.15.1 COMPANY SNAPSHOT 229
17.15.2 PRODUCT PORTFOLIO 229
17.15.3 RECENT DEVELOPMENT 229
17.16 GENNOVA BIOPHARMACEUTICALS LIMITED 230
17.16.1 COMPANY SNAPSHOT 230
17.16.2 PRODUCT PORTFOLIO 230
17.16.3 RECENT DEVELOPMENTS 230
17.17 HANGZHOU JIUYUAN GENE ENGINEERING CO., LTD. 231
17.17.1 COMPANY SNAPSHOT 231
17.17.2 PRODUCT PORTFOLIO 231
17.17.3 RECENT DEVELOPMENTS 231
17.18 INTAS PHARMACEUTICALS LTD. 232
17.18.1 COMPANY SNAPSHOT 232
17.18.2 PRODUCT PORTFOLIO 232
17.18.3 RECENT DEVELOPMENT 232
17.19 KASHIV BIOSCIENCES, LLC. 233
17.19.1 COMPANY SNAPSHOT 233
17.19.2 PRODUCT PORTFOLIO 233
17.19.3 RECENT DEVELOPMENT 233
17.20 KYOWA KIRIN CO., LTD. 234
17.20.1 COMPANY SNAPSHOT 234
17.20.2 REVENUE ANALYSIS 234
17.20.3 PRODUCT PORTFOLIO 235
17.20.4 RECENT DEVELOPMENT 235
17.21 LUPIN 236
17.21.1 COMPANY SNAPSHOT 236
17.21.2 REVENUE ANALYSIS 236
17.21.3 PRODUCT PORTFOLIO 237
17.21.4 RECENT DEVELOPMENT 237
17.22 MUNDIPHARMA INTERNATIONAL. 238
17.22.1 COMPANY SNAPSHOT 238
17.22.2 PRODUCT PORTFOLIO 238
17.22.3 RECENT DEVELOPMENT 238
17.23 NAPP PHARMACEUTICALS LIMITED 239
17.23.1 COMPANY SNAPSHOT 239
17.23.2 PRODUCT PORTFOLIO 239
17.23.3 RECENT DEVELOPMENT 239
17.24 RELIANCE LIFE SCIENCES 240
17.24.1 COMPANY SNAPSHOT 240
17.24.2 PRODUCT PORTFOLIO 240
17.24.3 RECENT DEVELOPMENTS 240
17.25 SANDOZ INTERNATIONAL GMBH 241
17.25.1 COMPANY SNAPSHOT 241
17.25.2 REVENUE ANALYSIS 241
17.25.3 PRODUCT PORTFOLIO 242
17.25.4 RECENT DEVELOPMENTS 242
17.26 SPECTRUM PHARMACEUTICALS, INC. 243
17.26.1 COMPANY SNAPSHOT 243
17.26.2 PRODUCT PORTFOLIO 243
17.26.3 RECENT DEVELOPMENT 243
17.27 USV PRIVATE LIMITED 244
17.27.1 COMPANY SNAPSHOT 244
17.27.2 PRODUCT PORTFOLIO 244
17.27.3 RECENT DEVELOPMENTS 244
18 QUESTIONNAIRE 245
19 RELATED REPORTS 248

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET: 59
TABLE 2 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 76
TABLE 3 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 77
TABLE 4 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 77
TABLE 5 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 79
TABLE 6 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION) 79
TABLE 7 LATIN AMERICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 8 LATIN AMERICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 9 LATIN AMERICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 10 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 82
TABLE 11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION) 86
TABLE 12 LATIN AMERICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 13 LATIN AMERICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 88
TABLE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 92
TABLE 15 LATIN AMERICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 16 LATIN AMERICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 94
TABLE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION) 98
TABLE 18 LATIN AMERICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 99
TABLE 19 LATIN AMERICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 100
TABLE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION) 104
TABLE 21 LATIN AMERICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 105
TABLE 22 LATIN AMERICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 23 LATIN AMERICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 106
TABLE 24 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 107
TABLE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 111
TABLE 26 LATIN AMERICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 112
TABLE 27 LATIN AMERICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 113
TABLE 28 LATIN AMERICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION) 113
TABLE 29 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION) 114
TABLE 30 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 119
TABLE 31 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION) 119
TABLE 32 LATAM G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION) 119
TABLE 33 LATAM G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 119
TABLE 34 LATAM NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 120
TABLE 35 LATAM ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 120
TABLE 36 LATAM G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 120
TABLE 37 LATAM G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 121
TABLE 38 LATAM G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 121
TABLE 39 LATAM G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 121
TABLE 40 LATAM G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 121
TABLE 41 MEXICO G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122
TABLE 42 MEXICO NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 122
TABLE 43 MEXICO ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 123
TABLE 44 MEXICO G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 123
TABLE 45 MEXICO MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 123
TABLE 46 MEXICO G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 123
TABLE 47 MEXICO SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
TABLE 48 MEXICO INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
TABLE 49 MEXICO G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 124
TABLE 50 MEXICO PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 124
TABLE 51 MEXICO G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 125
TABLE 52 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 125
TABLE 53 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 125
TABLE 54 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 125
TABLE 55 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 56 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
TABLE 57 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 126
TABLE 58 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 126
TABLE 59 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 126
TABLE 60 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
TABLE 61 MEXICO G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 127
TABLE 62 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 127
TABLE 63 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 127
TABLE 64 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 127
TABLE 65 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
TABLE 66 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 128
TABLE 67 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 128
TABLE 68 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 128
TABLE 69 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 129
TABLE 70 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 129
TABLE 71 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130
TABLE 72 COLUMBIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 130
TABLE 73 COLUMBIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 131
TABLE 74 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 131
TABLE 75 COLUMBIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 131
TABLE 76 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 131
TABLE 77 COLUMBIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
TABLE 78 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 132
TABLE 79 COLUMBIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 132
TABLE 80 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 132
TABLE 81 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 82 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
TABLE 83 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 133
TABLE 84 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 133
TABLE 85 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 133
TABLE 86 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
TABLE 87 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 134
TABLE 88 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 134
TABLE 89 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 134
TABLE 90 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 134
TABLE 91 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
TABLE 92 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 135
TABLE 93 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 135
TABLE 94 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 135
TABLE 95 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 136
TABLE 96 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 136
TABLE 97 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 136
TABLE 98 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 136
TABLE 99 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 136
TABLE 100 BRAZIL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137
TABLE 101 BRAZIL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 137
TABLE 102 BRAZIL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 138
TABLE 103 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION) 138
TABLE 104 BRAZIL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 138
TABLE 105 BRAZIL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION) 138
TABLE 106 BRAZIL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
TABLE 107 BRAZIL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION) 139
TABLE 108 BRAZIL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 139
TABLE 109 BRAZIL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION) 139
TABLE 110 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
TABLE 111 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 140
TABLE 112 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 140
TABLE 113 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 140
TABLE 114 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
TABLE 115 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 141
TABLE 116 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 141
TABLE 117 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 141
TABLE 118 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 142
TABLE 119 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION) 142
TABLE 120 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 142
TABLE 121 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 142
TABLE 122 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143
TABLE 123 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 143
TABLE 124 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 143
TABLE 125 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 143
TABLE 126 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION) 144
TABLE 127 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD) 144
TABLE 128 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS) 144
TABLE 129 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145
TABLE 130 ARGENTINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION) 145